Showing 5251-5260 of 8126 results for "".
- New Tattoo Survey Shows Tattoo Acceptance Up; Tattoo Regret Still an Issuehttps://practicaldermatology.com/news/new-tattoo-survey-shows-tattoo-acceptance-up-tattoo-regret-still-an-issue/2458826/With nearly 40 percent of Americans ages 18-29 sporting ink, body art has not only become mainstream, but can actually up someone's stock. In a recent Syneron Candela survey, attitudes toward people with tattoos were overwhelmingly positive, being described as artistic and creative (50 percen
- FDA Approves Yervoy for Adjuvant Treatment for Fully Resected Stage III Melanomahttps://practicaldermatology.com/news/fda-approves-yervoy-for-adjuvant-treatment-for-fully-resected-stage-iii-melanoma/2458829/The FDA approved Bristol-Myers Squibb Company’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1mm who have undergone complete resection including total lymphadenectomy. Th
- Phase 3 Data Show Promius Pharma's DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasishttps://practicaldermatology.com/news/phase-3-data-show-promius-pharmas-dfd-01-met-primary-endpoints-for-the-treatment-of-moderate-psoriasis/2458833/Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both stud
- Celgene Announces Results From Ongoing Phase 3 LIBERATE Trial of Otezla for Psoriasishttps://practicaldermatology.com/news/celgene-announces-results-from-ongoing-phase-3-liberate-trial-of-otezla-for-psoriasis/2458838/Results from Celgene Corporation’s ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis presented at 24th European Academy of Dermatology and Venereology show that half of psoriasis patients treated with oral Otezla achieved PASI
- Data Demonstrate Efficacy of ON Light Sciences, Inc.'s DeScribe Transparent PFD Patchhttps://practicaldermatology.com/news/data-demonstrate-efficacy-of-on-light-sciences-incs-describe-transparent-pfd-patch/2458839/Results of a clinical study evaluating the potential role of a Perfluorodecalin (PFD)-infused gel patch in laser-assisted tattoo removal were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting. “It is estimated that close to 25% of the US population has
- OHSU Releases Mole Mapper App to Track Potential Skin Cancershttps://practicaldermatology.com/news/ohsu-releases-mole-mapper-app-to-track-potential-skin-cancers/2458843/Oregon Health & Science University released an iPhone app it says is designed to advance melanoma research by giving users the ability to accurately measure and monitor moles, and contribute photos of how their potential trouble spots evolve over time. Called Mole Mapper, the app is free to d
- Fibrocell and Intrexon: Highlights of Pre-Clinical Data for Potential First-in-Class Treatment for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-and-intrexon-highlights-of-pre-clinical-data-for-potential-first-in-class-treatment-for-recessive-dystrophic-epidermolysis-bullosa/2458847/Fibrocell Science, Inc., and Intrexon Corporation are highlighting a poster entitled “Pre-Clinical Development of a Genetically-Modified Human Dermal Fibroblast (FCX-007) for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)” being presented at the American Society of
- Novan Appoints Chief Financial Officer and Chief Commercial Officer to Leadership Teamhttps://practicaldermatology.com/news/novan-appoints-chief-financial-officer-and-chief-commercial-officer-to-leadership-team/2458851/Novan Therapeutics appointed two new executives from the dermatology industry to the company's leadership team. Richard Peterson has joined the company as Chief Financial Officer and Brian Johnson as Chief Commercial Officer. Mr. Peterson will be responsible for the company's financi
- New Therapeutic Skin Care Line From Galdermahttps://practicaldermatology.com/news/new-therapeutic-skin-care-line-from-galderma/2458852/Galderma Laboratories, LP, makers of Cetaphil, unveiled a new therapeutic skincare line precisely engineered for challenged skin—Excipial. It will be available over the counter and without a prescription. Excipial products are formulated with ingredients to heal, relieve, protect, and repai
- Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereologyhttps://practicaldermatology.com/news/dermira-presents-data-from-drm01-phase-2a-trial-at-european-academy-of-dermatology-and-venereology/2458853/Topline data from a Phase 2a study showed that Dermira’s DRM01, a novel topical sebum inhibitor in development for the treatment of acne, met all of the primary efficacy endpoints, demonstrating statistically significant improvements relative to vehicle in the reduction of lesion counts and